Next generation approaches to achondroplasia care Oral FGFR3-targeted therapies are emerging as a potential step forward, offering more precise, convenient treatment options for children.

https://www.drugdiscoverynews.com/next-generation-approaches-to-achondroplasia-care-17104 Achondroplasia is the most common genetic form of short-limbed skeletal dysplasia, affecting an estimated 4.6 per 100,000 births worldwide. The condition arises from a gain-of-function mutation in FGFR3 (fibroblast growth factor receptor 3), which disrupts endochondral ossification and leads to characteristic short stature and limb proportions. Beyond stature, individuals with achondroplasia may face complications across the lifespan, including foramen magnum stenosis, spinal canal narrowing, sleep-disordered breathing, and challenges with activities of daily living, all of which can impact quality of life and necessitate multidisciplinary care.